Lixisenatide

PBAC's latest decision on Lixisenatide: Recommended with restriction (2014). Considered for Treatment of type 2 diabetes in combination with insulin, in patients with inadequate glycaemic control despite treatment with insulin and oral antidiabetic agents.

Eligible population

Adults with type 2 diabetes insufficiently controlled with basal insulin, with or without oral antidiabetic agents (metformin, sulphonylurea), requiring intensification of insulin therapy.

Therapy area

Endocrinology

Line of therapy

Later-line

Evidence base

RCT

Primary endpoint

HbA1c

Pivotal trial size

1,539 patients

Key trials

GetGoal-L, GetGoal-DUO 1, GetGoal-L-Asia, Owens 2011, Ligthelm 2011, Robbins 2007, Rosenstock 2008

Comparator

rapid-acting/short-acting components of basal-bolus insulin regimens and premixed insulin

Economic model

Cost-minimisation

ICER note

Cost minimisation analysis was performed (not a cost-utility or cost-effectiveness analysis). No ICER in AUD per QALY or LY was stated.

Submission history

• Jul 2014: Recommended with restriction · Authority Required
• Jul 2014: Recommended with restriction · Authority Required

Similar precedents

• Insulin glargine with lixisenatide
  similarity 0.85
• Exenatide
  similarity 0.77
• Empagliflozin with linagliptin
  similarity 0.77
• Linagliptin
  similarity 0.76
• Sitagliptin
  similarity 0.75
• Liraglutide
  similarity 0.75